Boston Scientific Settles $610M Tax Dispute
The giant device-maker has settled a long-running dispute over transfer pricing with the US Internal Revenue Service. Boston Scientific expects to pay almost $610m in back taxes and interest.
You may also be interested in...
Boston Sci plans to pay $275m to settle transfer-pricing disputes with the US Internal Revenue Service. A financial analyst views the settlement as a win for the company because it’s well below what the IRS initially sought.
On this week’s podcast, senior reporter Elizabeth Orr highlights the most exciting medical device technology coming down the pike as part of the US FDA’s Breakthrough Devices Program.
New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.